CVN766, the Selective Orexin-1-Receptor Antagonist Progressed to Clinical Investigations

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2024; 20(05): 0531
DOI: 10.1055/s-0043-1763722

Innovative Drug Discovery and Development

(Roche), Contributor(s):

Antonia F. Stepan

,

Seong Heon Kim

orexin-receptor antagonist - orexin - selective antagonist - CVN766 - clinical candidate - psychiatric disorders

Article published online:
15 April 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany